The National Osteoporosis Guideline Group (NOGG), established in 2007, is a multidisciplinary group that includes patient representation and professionals involved in the care of people with osteoporosis. NOGG provides a clinical guideline that reviews the assessment and diagnosis of osteoporosis, the therapeutic interventions available and the approaches for the prevention of fragility fractures, in postmenopausal women, and in men aged 50 years or older.
In October 2021 NICE reaccredited the process used by the National Osteoporosis Guideline Group to produce this clinical guideline for the prevention and treatment of osteoporosis.
Contents of the Clinical Guideline: NOGG 2021
- Duration and monitoring of bisphosphonate treatment
- Reassessment of fracture risk in individuals on osteoporosis drug treatment
- Rare adverse effects of long-term bisphosphonate and denosumab treatment
- Glucocorticoid-induced osteoporosis
- Men receiving androgen-deprivation therapy
- Women receiving aromatase inhibitor therapy
The NOGG guideline is intended for all healthcare professionals involved in the prevention and treatment of osteoporosis and fragility fractures. This includes primary care practitioners, allied health professionals and relevant specialists in secondary care including rheumatologists, gerontologists, gynaecologists, endocrinologists, clinical biochemists and orthopaedic surgeons. The guideline includes recommendations for training in osteoporosis care.
The guideline is supported by a series of Frequently Asked Questions (FAQs)
Access FAQsStay updated about NOGG recommendations
Website supported by the Royal Osteoporosis Society
